Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

AC Immune Reports Interim Results From Phase 2 Trial Of ACI-7104.056 Active Immunotherapy In Early Parkinson's Disease; Well Tolerated With No Clinically Relevant Safety Issues Reported, Says 100% Of Patients Responded Against The Target Antigen

Author: Benzinga Newsdesk | November 14, 2024 08:08am

Posted In: ACIU